ECSP066878A - [hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa - Google Patents
[hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasaInfo
- Publication number
- ECSP066878A ECSP066878A EC2006006878A ECSP066878A ECSP066878A EC SP066878 A ECSP066878 A EC SP066878A EC 2006006878 A EC2006006878 A EC 2006006878A EC SP066878 A ECSP066878 A EC SP066878A EC SP066878 A ECSP066878 A EC SP066878A
- Authority
- EC
- Ecuador
- Prior art keywords
- compound
- formula
- present
- inhibitor
- relates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención incluye el compuesto de fórmula I: (I)o un profármaco, farmacéuticamente aceptable o solvato de dicho compuesto. Además, la presente invención se refiere a una composición farmacéutica que comprende una cantidad farmacéuticamente eficaz del compuesto de fórmula I, y un vehículo farmacéuticamente aceptable. Además, la presente invención se refiere al uso de un compuesto de fórmula I como inhibidor de triptasa, que comprende introducir el compuesto en una composición que comprende triptasa. Además, la presente invención se refiere al uso de un compuesto de fórmula I para tratar a un paciente que padece o propenso a padecer una afección fisiológica que necesita la mejora de un inhibidor de triptasa que comprende administrar al paciente una cantidad terapéuticamente eficaz del compuesto de la reivindicación 1.La presente invención también se refiere a la preparación de un compuesto de fórmula I.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US55692704P | 2004-03-26 | 2004-03-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP066878A true ECSP066878A (es) | 2006-11-24 |
Family
ID=34964263
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2006006878A ECSP066878A (es) | 2004-03-26 | 2006-09-22 | [hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa |
Country Status (25)
Country | Link |
---|---|
US (1) | US20070142435A1 (es) |
EP (1) | EP1737848A1 (es) |
JP (1) | JP2007530580A (es) |
KR (1) | KR20060130682A (es) |
CN (1) | CN1956978A (es) |
AR (1) | AR048336A1 (es) |
AU (1) | AU2005230934A1 (es) |
BR (1) | BRPI0509245A (es) |
CA (1) | CA2560649A1 (es) |
CR (1) | CR8603A (es) |
DO (1) | DOP2005000039A (es) |
EC (1) | ECSP066878A (es) |
IL (1) | IL178031A0 (es) |
MA (1) | MA28547B1 (es) |
MX (1) | MXPA06010610A (es) |
NO (1) | NO20064811L (es) |
PA (1) | PA8627601A1 (es) |
PE (1) | PE20060084A1 (es) |
RU (1) | RU2330034C1 (es) |
TN (1) | TNSN06278A1 (es) |
TW (1) | TW200602035A (es) |
UA (1) | UA83738C2 (es) |
UY (1) | UY28821A1 (es) |
WO (1) | WO2005097780A1 (es) |
ZA (1) | ZA200607752B (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20071148A1 (es) * | 2006-03-29 | 2007-12-10 | Sanofi Aventis | Mejoras en la preparacion de intermedios que conducen a hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona |
AR065616A1 (es) * | 2007-03-07 | 2009-06-17 | Sanofi Aventis | Sintesis regioselectiva de ullmann de acido 4- bromo-3- metil-5- propoxi- tiofeno-2- carboxilico |
WO2008115912A1 (en) * | 2007-03-21 | 2008-09-25 | Sanofi-Aventis | Regio-specific synthesis of 4-bromo-3-methyl-5-propoxy-thiophene-2-carboxylic acid |
AR065858A1 (es) * | 2007-03-29 | 2009-07-08 | Sanofi Aventis | Metodo para preparar el inhibidor de triptasa [ 4-(5-aminoetil-2-fluoro-fenil)-piperidin-1-il]-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona. |
WO2008121669A1 (en) * | 2007-03-29 | 2008-10-09 | Sanofi-Aventis | 4-bromo-3-methyl-5-propoxythiophene-2-carboxylic acid 2,5-dioxo-pyrrolidin-1-yl ester, its regio-specific synthesis and intermediate thereto |
JP2011504499A (ja) * | 2007-11-21 | 2011-02-10 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | トリプターゼ阻害剤として使用するためのスピロピペリジン |
EP2242477B1 (en) * | 2008-01-24 | 2013-01-02 | Soligenix, Inc. | Topically active steroids for use in interstitial pulmonary fibrosis |
NZ591234A (en) * | 2008-08-22 | 2012-03-30 | Sanofi Aventis | [4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-[7-fluoro-1-(2-methoxy-ethyl)-4-trifluoromethoxy-1h-indol-3-yl]-methanone as an inhibitor of mast cell tryptase |
AR074776A1 (es) | 2008-12-18 | 2011-02-09 | Sanofi Aventis | Metodo para tratar la degeneracion macular; modulando el sistema inmunitario del paciente |
FR2955324A1 (fr) * | 2010-01-15 | 2011-07-22 | Sanofi Aventis | [4-(5-aminomethyl-phenyl)-piperidin-1-yl]-1h-indol-3-yl]-methanones disubstituees |
MY155682A (en) * | 2009-09-24 | 2015-11-13 | Sanofi Aventis Us Llc | Synthesis of (4-fluoro-3-piperidin-4-yl-benzyl)-carbamic acid tert-butyl ester and intermediates thereof |
JP2013515724A (ja) * | 2009-12-23 | 2013-05-09 | サノフイ | ベータ−トリプターゼ阻害剤としてのトロピノンベンジルアミン類 |
MX2012006805A (es) * | 2009-12-23 | 2012-07-10 | Sanofi Sa | Indolil-piperidinil bencilaminas como inhibidores de beta-triptasa. |
CA2785434A1 (en) * | 2009-12-23 | 2011-06-30 | Sanofi | Treatment for inflammatory bowel disease |
EP2538942A1 (en) * | 2010-02-24 | 2013-01-02 | Sanofi | Treatment of dermatological allergic conditions |
BR122022001219B1 (pt) | 2011-10-07 | 2023-03-14 | Takeda Pharmaceutical Company Limited | Composição farmacêutica, uso da composição farmacêutica, combinação, e, uso da combinação |
US10738131B2 (en) * | 2017-02-10 | 2020-08-11 | Genentech, Inc. | Anti-tryptase antibodies, compositions thereof, and uses thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0012362D0 (en) * | 2000-05-22 | 2000-07-12 | Aventis Pharma Ltd | Chemical compounds |
WO2001090101A1 (en) * | 2000-05-22 | 2001-11-29 | Aventis Pharmaceuticals Inc. | Arylmethylamine derivatives for use as tryptase inhibitors |
-
2005
- 2005-03-21 DO DO2005000039A patent/DOP2005000039A/es unknown
- 2005-03-22 PE PE2005000325A patent/PE20060084A1/es not_active Application Discontinuation
- 2005-03-23 AR ARP050101170A patent/AR048336A1/es not_active Application Discontinuation
- 2005-03-23 UY UY28821A patent/UY28821A1/es unknown
- 2005-03-24 AU AU2005230934A patent/AU2005230934A1/en not_active Abandoned
- 2005-03-24 KR KR1020067019886A patent/KR20060130682A/ko not_active Application Discontinuation
- 2005-03-24 EP EP05731154A patent/EP1737848A1/en not_active Withdrawn
- 2005-03-24 JP JP2007505191A patent/JP2007530580A/ja not_active Abandoned
- 2005-03-24 MX MXPA06010610A patent/MXPA06010610A/es not_active Application Discontinuation
- 2005-03-24 BR BRPI0509245-0A patent/BRPI0509245A/pt not_active IP Right Cessation
- 2005-03-24 WO PCT/US2005/009899 patent/WO2005097780A1/en active Application Filing
- 2005-03-24 CA CA002560649A patent/CA2560649A1/en not_active Abandoned
- 2005-03-24 RU RU2006137717/04A patent/RU2330034C1/ru not_active IP Right Cessation
- 2005-03-24 CN CNA2005800164250A patent/CN1956978A/zh active Pending
- 2005-03-24 UA UAA200611261A patent/UA83738C2/ru unknown
- 2005-03-25 TW TW094109209A patent/TW200602035A/zh unknown
- 2005-03-28 PA PA20058627601A patent/PA8627601A1/es unknown
-
2006
- 2006-09-07 CR CR8603A patent/CR8603A/es not_active Application Discontinuation
- 2006-09-12 TN TNP2006000278A patent/TNSN06278A1/en unknown
- 2006-09-12 IL IL178031A patent/IL178031A0/en unknown
- 2006-09-14 US US11/520,998 patent/US20070142435A1/en active Granted
- 2006-09-15 ZA ZA200607752A patent/ZA200607752B/en unknown
- 2006-09-22 EC EC2006006878A patent/ECSP066878A/es unknown
- 2006-10-20 MA MA29405A patent/MA28547B1/fr unknown
- 2006-10-23 NO NO20064811A patent/NO20064811L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CA2560649A1 (en) | 2005-10-20 |
AU2005230934A1 (en) | 2005-10-20 |
PA8627601A1 (es) | 2006-01-23 |
DOP2005000039A (es) | 2005-10-31 |
CR8603A (es) | 2007-06-08 |
UY28821A1 (es) | 2005-10-31 |
IL178031A0 (en) | 2006-12-31 |
TW200602035A (en) | 2006-01-16 |
KR20060130682A (ko) | 2006-12-19 |
UA83738C2 (en) | 2008-08-11 |
MA28547B1 (fr) | 2007-04-03 |
ZA200607752B (en) | 2008-05-28 |
RU2330034C1 (ru) | 2008-07-27 |
JP2007530580A (ja) | 2007-11-01 |
EP1737848A1 (en) | 2007-01-03 |
NO20064811L (no) | 2006-10-23 |
TNSN06278A1 (en) | 2007-12-03 |
BRPI0509245A (pt) | 2007-09-11 |
AR048336A1 (es) | 2006-04-19 |
RU2006137717A (ru) | 2008-05-10 |
US20070142435A1 (en) | 2007-06-21 |
CN1956978A (zh) | 2007-05-02 |
WO2005097780A1 (en) | 2005-10-20 |
PE20060084A1 (es) | 2006-03-09 |
MXPA06010610A (es) | 2006-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP066878A (es) | [hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa | |
ECSP088974A (es) | Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3) | |
WO2008022256A3 (en) | Methods and compositions for preventing or treating age-related diseases | |
WO2007062093A3 (en) | Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor | |
CU23821A3 (es) | Composición farmacéutica que comprende una difenilurea sustituida con omega-carboxiarilo para el tratamiento del cáncer | |
NO20025601D0 (no) | Arylmetylaminderivater for anvendelse som tryptaseinhibitorer | |
DE60332629D1 (de) | Phenyl-(4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yi)aminderivate | |
UA107578C2 (uk) | Комбінована терапія при лікуванні діабету | |
HK1087702A1 (en) | Arylmethylamine derivatives for use as tryptase inhibitors | |
UY28979A1 (es) | Derivados de hidrocloruros de 3-carboxamida, composiciones farmacéuticas que los contienen, procedimiento de preparación y su uso, útiles como inhibidores selectivos de gsk3 | |
GB0112348D0 (en) | Compounds | |
SG158863A1 (en) | Intravenous formulations of pde-5 inhibitors | |
HK1176318A1 (en) | Injection device | |
UA97348C2 (en) | HETEROCYCLIC NF-kB INHIBITORS | |
CO6341624A2 (es) | [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-[7-fluoro-1-(2-metoxi-etil)-4-trifluorometoxi-1h-indol-3-il]-metanona como un inhibidor de la triptasa de mastocitos | |
TW200800984A (en) | New compounds | |
AU2020278236A8 (en) | Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor | |
WO2006125194A3 (en) | Piperazine derivatives and their uses as therapeutic agents | |
UA89795C2 (ru) | Фармацевтическая композиция, которая содержит эстер темозоломида | |
TW200640465A (en) | New pharmaceutically active compounds for the treatment of respiratory diseases | |
UY30847A1 (es) | Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales | |
MY156278A (en) | Disubstituted [4-(5-aminomethyl-phenyl)-piperidin-1-yl]-1h-indol-3-yl]-methanones | |
DE602004022578D1 (de) | Antitumorale terpen-verbindungen | |
AR062215A1 (es) | Inhibidor de trombina activo por via oral | |
SE0401716D0 (sv) | New compounds |